<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03802461</url>
  </required_header>
  <id_info>
    <org_study_id>18-5177</org_study_id>
    <nct_id>NCT03802461</nct_id>
  </id_info>
  <brief_title>Effectiveness of Fecal Flora Alteration for Eradication of Carbapenemase-producing Enterobacteriaceae Colonization</brief_title>
  <acronym>EFFECT-CPE</acronym>
  <official_title>Effectiveness of Fecal Flora Alteration for Eradication of Carbapenemase-producing Enterobacteriaceae Colonization Trial (EFFECT-CPE): a Multisite, Open-label, Randomized Controlled Feasibility Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susy Hota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sinai Health System, Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto, Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Toronto Invasive Bacterial Diseases Network, Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health Ontario Laboratories, Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carbapenemase-producing Enterobacteriaceae (CPE) are bacteria carried in the gastrointestinal&#xD;
      tract that are resistant to carbapenems, antibiotics of last resort. CPE infections result in&#xD;
      death in 25-50% of cases. Fecal microbiota transplantation (FMT) is the transfer of stool&#xD;
      from a healthy donor to a recipient to alter the composition of gut microbes. Early studies&#xD;
      support its use for eliminating CPE carriage but definitive studies are lacking. The&#xD;
      investigators propose a feasibility pilot for a multicenter, non-blinded randomized trial&#xD;
      comparing the effectiveness of FMT with no intervention (standard of care) in eliminating&#xD;
      intestinal carriage of CPE. Forty patients with CPE will be randomly assigned to receive FMT&#xD;
      by enema or no intervention. Feasibility will be demonstrated by the ability to recruit and&#xD;
      retain 40 patients over 12 months, and to provide FMT made at a central site to at least one&#xD;
      off-site hospital. The primary clinical endpoint for the full trial is CPE intestinal&#xD;
      carriage 3 months after the intervention. Secondary endpoints include: CPE carriage at 1, 6&#xD;
      and 12 months; time to decolonization of CPE; safety; CPE infections over 12 months; and,&#xD;
      intestinal carriage of other antibiotic-resistant organisms. Data on the clinical outcomes&#xD;
      will be collected but not analyzed in this feasibility study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multisite, open-label randomized controlled internal pilot trial designed to assess&#xD;
      the feasibility of a larger trial aimed at determining the effectiveness of fecal microbiota&#xD;
      transplantation (FMT) by enema in short and long term intestinal decolonization of&#xD;
      carbapenemase-producing Enterobacteriaceae (CPE). Forty (40) asymptomatic adult patients&#xD;
      intestinally colonized with CPE will be allocated in a 1:1 ratio to receive a bowel&#xD;
      preparation followed by FMT by enema route, versus standard of care (no intervention). FMT&#xD;
      will be provided by the University of Toronto Microbiota Therapeutics Outcomes Program&#xD;
      (MTOP), using standardized operating procedures for recruiting and screening FMT donors,&#xD;
      manufacturing FMT and administering FMT by enema. The feasibility outcomes are: successful&#xD;
      randomization of 40 patients within 12 months, retention of &gt;90% (36/40) of patients up to 6&#xD;
      months, and provision of FMT at a non-primary study site in at least one patient. Data on the&#xD;
      clinical and exploratory outcomes will be collected but not analyzed in this pilot study. The&#xD;
      primary clinical outcome is incidence of intestinal decolonization of CPE at 3 months.&#xD;
      Secondary clinical outcomes include: time to decolonization of CPE; incidence of CPE clinical&#xD;
      infections up to 12 months post-intervention; incidence of intestinal decolonization of CPE&#xD;
      and other antibiotic-resistant organisms (extended spectrum beta-lactamase Enterobacteriaceae&#xD;
      - ESBLs and vancomycin-resistant Enterococci - VRE) at 1, 3, 6 and 12 months&#xD;
      post-intervention; and, safety profile. As an exploratory outcome, changes in fecal&#xD;
      microbiome composition will be examined before and after intervention. This study leverages&#xD;
      existing support, research infrastructures and expertise - including the Toronto Invasive&#xD;
      Bacterial Diseases Network (TIBDN), Toronto Antimicrobial Resistance Research Network&#xD;
      (TARRN), and the University of Toronto Microbiota Therapeutics Outcomes Program (MTOP) - to&#xD;
      optimize feasibility regarding patient recruitment and FMT administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Temporarily on hold due to COVID-19 pandemic&#xD;
  </why_stopped>
  <start_date type="Actual">March 22, 2019</start_date>
  <completion_date type="Anticipated">December 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Asymptomatic adult patients intestinally colonized with CPE will either randomized to receive fecal microbiota transplantation (intervention) or standard of care (no intervention).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of intestinal colonization of patients with CPE 3 months after intervention.</measure>
    <time_frame>3 months</time_frame>
    <description>Incidence of CPE colonization in FMT arm vs control arm at 3 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Randomization rate in study</measure>
    <time_frame>12 months</time_frame>
    <description>Completion of randomization of 40 study participants during the study period will be used to indicate feasibility of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients retained in study for up to 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>A retention of 90% of patients up to 6 months in the study will be used to indicate feasibility.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of CPE decolonization in FMT-treatment and non-treatment groups at 1, 6 and 12 months.</measure>
    <time_frame>1, 6, and 12 months</time_frame>
    <description>As above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CPE decolonization in FMT-treatment and non-treatment groups.</measure>
    <time_frame>1, 3, 6, and 12 months</time_frame>
    <description>As above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of CPE clinical infection in FMT treatment and non-treatment groups over 12 months.</measure>
    <time_frame>1, 3, 6, and 12 months</time_frame>
    <description>As above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of extended spectrum beta-lactamase organisms (ESBL) and vancomycin-resistant Enterococci (VRE) intestinal colonization at 0, 1, 3, 6 and 12 months in FMT treatment and non-treatment groups.</measure>
    <time_frame>1, 3, 6, and 12 months</time_frame>
    <description>Changes in colonization status of other antimicrobial resistant organisms over the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of solicited and unsolicited adverse and serious adverse events in both groups</measure>
    <time_frame>3 months</time_frame>
    <description>Participants will be asked to report adverse and serious adverse events will be throughout the study period and will be asked specifically about adverse events during study visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with all-cause mortality at 30 days post-randomization</measure>
    <time_frame>1 month</time_frame>
    <description>As above</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in composition and diversity of fecal bacterial phyla (as measured by 16s ribosomal ribonucleic acid sequencing) in both intervention groups</measure>
    <time_frame>12 months</time_frame>
    <description>As above</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>Fecal Microbiota Transplantation (FMT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bowel lavage preparation followed by FMT administered by enema, given on 3 occasions. Fecal filtrate for FMT will be prepared from 50 g of healthy donor stool, homogenized, and diluted in 300 mL sterile normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in this arm will not receive intervention and will be on standard of care .</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation (FMT)</intervention_name>
    <description>Feces from healthy donor</description>
    <arm_group_label>Fecal Microbiota Transplantation (FMT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. ≥ 1 rectal swab, groin, stool, or urine specimen positive for a CPE within the past 1&#xD;
             month.&#xD;
&#xD;
             • Presence of CPE will be confirmed at baseline through collection of pooled&#xD;
             groin/rectal swab and urine specimen.&#xD;
&#xD;
          3. Women of childbearing age must be using at least one reliable form of birth control.&#xD;
&#xD;
          4. Must be able to provide informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active infection with CPE at the time of assessment.&#xD;
&#xD;
          2. Pregnancy, planned pregnancy or breastfeeding.&#xD;
&#xD;
          3. Current admission to intensive care unit.&#xD;
&#xD;
          4. Significantly immunocompromised patients .&#xD;
&#xD;
               -  neutropenia (ANC &lt; 1)&#xD;
&#xD;
               -  ongoing use of systemic corticosteroids &gt; 30 mg/day&#xD;
&#xD;
               -  ongoing use of biologic therapy&#xD;
&#xD;
               -  undergoing chemotherapy, received chemotherapy ≤ 30 days from baseline visit, or&#xD;
                  expected to undergo chemotherapy in the upcoming 12 months&#xD;
&#xD;
               -  active hematologic malignancy&#xD;
&#xD;
               -  solid organ transplant recipient&#xD;
&#xD;
               -  hematopoetic stem cell transplant recipient&#xD;
&#xD;
               -  HIV positive patients with cluster differentiation 4 (CD4) cell count &lt; 350&#xD;
&#xD;
          5. Patients with ascites or receiving peritoneal dialysis.&#xD;
&#xD;
          6. History of inflammatory bowel disease (Crohn's or Ulcerative colitis).&#xD;
&#xD;
          7. Chronic diarrhea or active colitis for any reason.&#xD;
&#xD;
          8. Ileus or active gastrointestinal motility disorder at baseline.&#xD;
&#xD;
          9. History of total colectomy.&#xD;
&#xD;
         10. Severe, irreversible bleeding disorder.&#xD;
&#xD;
         11. History of anaphylactic or anaphylactoid allergic reaction to any foods.&#xD;
&#xD;
         12. Anticipated life expectancy less than 6 months.&#xD;
&#xD;
         13. Unable to tolerate enema.&#xD;
&#xD;
         14. Participant is not a Canadian citizen or permanent resident, and not expected to&#xD;
             remain in Toronto region for 12 months.&#xD;
&#xD;
         15. Any reason in the view of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susy S. Hota, MD MSc FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases Physician, University Health Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan M. Poutanen, MD MPH FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Microbiologist &amp; Infectious Disease Physician, Sinai Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Osler Health System</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joseph Brant Hospital</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7S 1W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MacKenzie Health</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4C 4Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Scarborough Hospital</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1P 2T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North York General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2K 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael Garron Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Health Ontario Laboratories</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Health System</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Health Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6R 1B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>Susy Hota</investigator_full_name>
    <investigator_title>Medical Director, Infection Prevention and Control</investigator_title>
  </responsible_party>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <keyword>Gut Microbiome</keyword>
  <keyword>Carbapenemase-producing Enterobacteriaceae (CPE)</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

